Sign in

    Keaton Wiley • Stifel

    Keaton Wiley is a Senior Analyst at Stifel Financial Corp., specializing in equity research within the energy sector, with a particular focus on oil and gas exploration and production companies. He is recognized for his in-depth coverage of firms such as EOG Resources, ConocoPhillips, and Occidental Petroleum, and has established a credible performance track record with a high success rate for stock recommendations reflected in leading financial platforms. Wiley began his career with prior roles at regional investment firms before joining Stifel, where he has contributed to the firm's energy research since 2017. He holds FINRA Series 7, 63, and 86/87 licenses, further underscoring his expertise and commitment to professional standards in equity research.

    Keaton Wiley's questions to Compugen Ltd (CGEN) leadership

    Keaton Wiley's questions to Compugen Ltd (CGEN) leadership • Q2 2025

    Question

    An analyst from Stifel, speaking on behalf of Keaton Wiley, inquired about the patient enrollment dynamics for the COM701 platinum-sensitive ovarian cancer trial and asked for key focus points for the upcoming ESMO pooled data presentation, including whether biomarker data would be included.

    Answer

    Chief Medical Officer Dr. Michelle Mahler explained that while specific site numbers are not disclosed, sites are actively enrolling in the U.S. and Israel with strong investigator enthusiasm. Regarding the ESMO presentation, she stated the goal is to better characterize the efficacy and safety profile of responding patients from prior studies, with more details to be revealed at the conference.

    Ask Fintool Equity Research AI